Brazil gears up for embryonic R&D "production"
This article was originally published in Clinica
Brazil is a step closer to activating its national embryo "production" system (SisEmbrio), paving the way for an ambitious programme of cell and tissue regeneration R&D (see Clinica No 1307, p 12). A survey of the country's cell and regenerative tissue banks (BCTGs) and its 120 or so assisted reproduction clinics, conducted to establish the number of supernumerary embryos available nationally for such research, concluded last week. These facilities will now be obliged to provide such information on an annual basis. The data will be used by SisEmbrio to, among other things, determine how many embryos are available for research use at any given time. Brazil's bioethics legislation (which was recently passed following a three-year judicial review) allows embryonic stem cell R&D provided that only supernumerary embryos that have been stored for at least three years, or new embryos defined as unviable, are used.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.